ASH 2025

Oncology

With over 8,200 abstracts accepted, ASH 2025 showcased breakthroughs in sickle cell disease, platelet disorders, and next-generation cell therapies.

News

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

News

The first cell therapy for severe aplastic anaemia – Gamida Cell's Omisirge – has been approved by the FDA.

News

Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.

News

Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.

News

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.